Browse drugs

…particularly relevant for GLP-1 receptor agonists. For example, semaglutide has demonstrated dose-dependent effects on glycemic control and…

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…

… (SGLT2i: adjusted median OR (aMOR) 1.29 (95% CI 1.23 to 1.36); GLP-1 RA: aMOR 1.48 (95% CI 1.37 to 1.62)). Treating all patients would …

…ristics and outcomes of patients with T2D and CKD who initiated SGLT2i or GLP-1 RA in China. The results are important for understandi…

…s. There is a rapid, largely hidden surge in direct-to-consumer GLP-1 RA use among patients with IBD. Integrated pathways and prospectiv…

…ul implementation of lifestyle interventions remains a barrier. Metformin is recommended for adults at increased risk of developing T2D; …

…inuric LN, SGLT2i may be added after disease stabilization, and GLP-1 RA are reserved for those with type 2 diabetes. MRA use is not sta…

…pants taking two medications, the most common combinations were metformin with a sulfonylurea (n=31 (27%) in the CGM group and n=21 (36%)…

…pairs), 30-day mortality was 0% vs. 11.1% (p<0.001).Conclusions Semaglutide use was associated with lower mortality following AIS in a larg…

…gly common worldwide. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) type drugs have the potential to help patients achieve conside…

…de (25 936), empagliflozin (715 802), sitagliptin (493 563) and glipizide (832 295) ( online supplemental eTable 1, 5–8). Baseline charac…